Cardiotoxicology remains a serious side effect in response to certain treatments as well as a major cause of clinical trial drug failures. iPSC-derived cardiomyocytes (CM) are powerful tool for studying the response of the human heart to different compounds in advance of clinical trials. Using human iPSC-CM, StemoniX creates functional cardiomyocyte spheroids to study the impact compounds have on the electrophysiology and structure of cardiomyocytes. 

​

Testing strategies include acute and chronic exposure with single or repeated dosing strategies as well as molecular, structural, cell health/viability, and functional endpoints to provide a holistic picture of compound impact on cardiac function.